Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY)

CAPS Rating: 4 out of 5

A global pharmaceutical company, which produces pharmaceutical ingredients and intermediates, finished dosage forms and biotechnology products and markets them globally. It conducts research in the areas of cancer, diabetes, cardiovascular disease etc.

Recs

1
Player Avatar NHWeston (< 20) Submitted: 4/2/2010 12:09:39 PM : Outperform Start Price: $28.31 RDY Score: +3.31

Dr. Reddy's is a rapidly growing player in the global generics market. For now, they virtually own their domestic market in India and, although overshadowed by more flashy companies like Teva, they are gaining market share in Europe and Latin America. Less celebrated but also important is - or so I'm told - they're doing some interesting original work in melanoma, diabetes, and cholera. I've also heard talk that they might be a t6ake-over candidate although the New Delhi government would pose an obstale here. 35 by Christmas. Regards.

Featured Broker Partners


Advertisement